Real‐World Use of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Early and Long‐Term Clinical, Renal, and Patient‐Reported Outcomes in an Italian Rheumatology–Nephrology Network
ACR Open Rheumatology · 2026-10 · 8 (10)
DOI: 10.1002/acr2.90126 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 11.10.2026. Verfasst von Luca Quartuccio und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Udine.
Abstract (Originalsprache)
Objective
Complement activation, particularly through the C5a–C5a receptor axis, plays a pivotal role in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and may represent an important therapeutic target. Avacopan, an oral C5a receptor antagonist, was the first therapy targeting this pathway to enter in clinical practice. Prospective real‐world data on its long‐term effectiveness, safety, and impact on quality of life (QoL) remain limited. In the context of an evolving therapeutic and regulatory landscape, such data provide valuable evidence on the clinical effects of C5a receptor inhibition and may inform the development and evaluation of future complement‐targeted therapies. The objective of this study was to evaluate the real‐world effectiveness, safety, kidney outcomes, and patient‐reported outcomes of avacopan in an Italian cohort of patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Methods
This prospective, multicenter, observational study included patients with newly diagnosed or relapsing GPA or MPA who were started on avacopan therapy across 18 Italian centers. Avacopan was administered in combination with standard immunosuppressive therapy, with or without glucocorticoids (GCs). Clinical remission (Birmingham Vasculitis Activity Score = 0), GC‐free remission, kidney parameters, laboratory outcomes, adverse events, and patient‐reported outcomes assessed by the AAV Patient‐Reported Outcome questionnaire were evaluated up to 52 weeks and beyond. Estimated glomerular filtration rate (eGFR) was calculated using the European Kidney Function Consortium equation.
Results
Forty‐six patients were included (63% women; mean age of 59 years); 61% had relapsing disease, and 70% had kidney involvement at baseline. Clinical remission was achieved by 78%, 88%, and 97% of patients at weeks 12, 26, and 52, respectively. GC‐free remission occurred in 20% at week 12 and 55% at week 52. Mean GC dose decreased from 23 mg/day at baseline to 5 mg/day by week 12 ( P < 0.001). Kidney function improved over time, with median eGFR increasing from 30.5 mL/min/1.73 m 2 at baseline to 53.5 mL/min/1.73 m 2 at week 52 ( P = 0.002). Significant improvements in QoL were observed as early as week 12 and were sustained until week 52, particularly in the physical function domain. Adverse events were mild to moderate; infections were the most frequent events (40%). Disease relapses were uncommon and occurred exclusively in patients treated for relapsing disease.
Conclusion
In this real‐world Italian cohort, patients treated with avacopan achieved high remission rates, substantial GC reduction, improvement in kidney function, and sustained QoL benefits. These findings provide prospective real‐world evidence on the clinical outcomes associated with C5a receptor inhibition in routine clinical practice while acknowledging the observational design of the study.
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy.
- Department of Medical Area, Institute of Statistics, University of Udine, Udine, Italy.
- Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy.
- Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
- Division of Rheumatology, Department of Internal Medicine and Therapeutics, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy.
ORCID-Profile: Chiara Marvisi, Florenzo Iannone, Augusto Vaglio, Sara Monti, Roberto Padoan, Carlo Salvarani
Förderung
- Università degli Studi di Udine
Zitieren
APA
Quartuccio, L., Treppo, E., Isola, M., De Martino, M., Marvisi, C., Iorio, L., Milanesi, A., Moroni, L., Conticini, E., Affatato, S., Urban, M. L., Tombetti, E., Barone, F., Esposito, P., Iannone, F., Binda, V., Castellano, G., Murtas, C., Tartaglione, L., …, & Italian Society of Rheumatology (Vasculitis and Polymyalgia Rheumatica Study Group) (2026). Real‐World Use of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Early and Long‐Term Clinical, Renal, and Patient‐Reported Outcomes in an Italian Rheumatology–Nephrology Network. ACR Open Rheumatology, 8(10). https://doi.org/10.1002/acr2.90126
Vancouver
Quartuccio L, Treppo E, Isola M, De Martino M, Marvisi C, Iorio L, et al. Real‐World Use of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Early and Long‐Term Clinical, Renal, and Patient‐Reported Outcomes in an Italian Rheumatology–Nephrology Network. ACR Open Rheumatology. 2026;8(10). doi:10.1002/acr2.90126
BibTeX
@article{Quartuccio2026,
author = {Quartuccio, Luca and Treppo, Elena and Isola, Miriam and De Martino, Maria and Marvisi, Chiara and Iorio, Luca and Milanesi, Alessandra and Moroni, Luca and Conticini, Edoardo and Affatato, Stefania and Urban, Maria Letizia and Tombetti, Enrico and Barone, Fabio and Esposito, Pasquale and Iannone, Florenzo and Binda, Valentina and Castellano, Giuseppe and Murtas, Corrado and Tartaglione, Lida and Monache, Francesco Delle and Rigon, Amelia and Panini, Maria Chiara and Allinovi, Marco and Vaglio, Augusto and Frediani, Bruno and Delvino, Paolo and Monti, Sara and Padoan, Roberto and Montecucco, Carlomaurizio and Dagna, Lorenzo and Emmi, Giacomo and Alberici, Federico and Salvarani, Carlo and Italian Society of Rheumatology (Vasculitis and Polymyalgia Rheumatica Study Group), Italian Society of Rheumatology (Vasculitis and Polymyalgia Rheumatica Study Group)},
title = {Real‐World Use of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Early and Long‐Term Clinical, Renal, and Patient‐Reported Outcomes in an Italian Rheumatology–Nephrology Network},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {10},
doi = {10.1002/acr2.90126}
}
EUVIMED